{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:14:31Z","timestamp":1740147271930,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Current evidence linking the development of Parkinson\u2019s disease after the use of 3,4-methylenedioxymethamphetamine is mixed and limited, with only a few positive case reports demonstrating this.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We examine this interesting case of a 49-year-old Chinese gentleman who used 3,4-methylenedioxymethamphetamine and subsequently developed early onset Parkinson\u2019s disease at age 38\u00a0years. He had a family history of Parkinson\u2019s disease, though the onset of his symptoms was significantly earlier than those of his family members. MDMA was a likely precipitating factor for the early onset of his symptoms. He then conversely used methamphetamines to augment his treatment of Parkinson\u2019s symptoms. In the treatment of his Parkinson\u2019s disease, dopamine replacement therapy and deep brain stimulation could perpetuate addictive behaviors such as dopamine dysregulation syndrome, and similarly perpetuate substance use in vulnerable individuals. He had also been diagnosed with a human immunodeficiency virus infection at age 43, and his antiretroviral therapy contributed to depressive symptoms, which then complicated the management of his substance use.<\/jats:p>\n                <jats:p>We examined the importance of managing his subsequent psychiatric and medical comorbidities to prevent their debilitating psychosocial impacts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case implies that 3,4-methylenedioxymethamphetamine use may precipitate the early development of Parkinson\u2019s disease in patients with genetic vulnerability. This highlights the risk in patients potentially paradoxically using substances to alleviate symptoms of Parkinson\u2019s, which can in turn perpetuate the disease process.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04147-x","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:02:09Z","timestamp":1695427329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early onset Parkinson\u2019s disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-7895","authenticated-orcid":false,"given":"Tianyi","family":"Hui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,23]]},"reference":[{"issue":"11","key":"4147_CR1","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/add.14708","volume":"114","author":"JM Lappin","year":"2019","unstructured":"Lappin JM, Sara GE. Psychostimulant use and the brain. Addiction. 2019;114(11):2065\u201377. https:\/\/doi.org\/10.1111\/add.14708. (Epub 2019 Jul 19).","journal-title":"Addiction"},{"issue":"12","key":"4147_CR2","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","volume":"15","author":"A Ascherio","year":"2016","unstructured":"Ascherio A, Schwarzschild MA. The epidemiology of Parkinson\u2019s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257\u201372. https:\/\/doi.org\/10.1016\/S1474-4422(16)30230-7. (Epub 2016 Oct 11).","journal-title":"Lancet Neurol"},{"issue":"18","key":"4147_CR3","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/nejm199905063401817","volume":"340","author":"S Mintzer","year":"1999","unstructured":"Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy. N Engl J Med. 1999;340(18):1443. https:\/\/doi.org\/10.1056\/nejm199905063401817.","journal-title":"N Engl J Med"},{"issue":"11","key":"4147_CR4","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/mds.10623","volume":"18","author":"P O'Suilleabhain","year":"2003","unstructured":"O\u2019Suilleabhain P, Giller C. Rapidly progressive Parkinsonism in a self-reported user of ecstasy and other drugs. Mov Disord. 2003;18(11):1378\u201381. https:\/\/doi.org\/10.1002\/mds.10623.","journal-title":"Mov Disord"},{"issue":"1","key":"4147_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1056\/NEJMc030208","volume":"349","author":"SM Kuniyoshi","year":"2003","unstructured":"Kuniyoshi SM, Jankovic J. MDMA and Parkinsonism. N Engl J Med. 2003;349(1):96\u20137. https:\/\/doi.org\/10.1056\/NEJMc030208.","journal-title":"N Engl J Med"},{"issue":"1","key":"4147_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1017\/cjn.2015.244","volume":"43","author":"LW Ferguson","year":"2016","unstructured":"Ferguson LW, Rajput AH, Rajput A. Early-onset vs. Late-onset Parkinson\u2019s disease: a clinical-pathological study. Can J Neurol Sci. 2016;43(1):113\u20139. https:\/\/doi.org\/10.1017\/cjn.2015.244. (Epub 2015 Jul 20).","journal-title":"Can J Neurol Sci"},{"issue":"11","key":"4147_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/mds.10643","volume":"18","author":"SJ Kish","year":"2003","unstructured":"Kish SJ. What is the evidence that Ecstasy (MDMA) can cause Parkinson\u2019s disease? Mov Disord. 2003;18(11):1219\u201323. https:\/\/doi.org\/10.1002\/mds.10643.","journal-title":"Mov Disord"},{"key":"4147_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1192\/bjp.175.1.63","volume":"175","author":"DM Semple","year":"1999","unstructured":"Semple DM, Ebmeier KP, Glabus MF, O\u2019Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (\u2018ecstasy\u2019) users. Br J Psychiatry. 1999;175:63\u20139. https:\/\/doi.org\/10.1192\/bjp.175.1.63.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"4147_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s0304-3940(02)00823-6","volume":"330","author":"WJ Schmidt","year":"2002","unstructured":"Schmidt WJ, Mayerhofer A, Meyer A, Kovar KA. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? Neurosci Lett. 2002;330(3):251\u20134. https:\/\/doi.org\/10.1016\/s0304-3940(02)00823-6.","journal-title":"Neurosci Lett"},{"key":"4147_CR10","doi-asserted-by":"publisher","first-page":"308052","DOI":"10.1155\/2013\/308052","volume":"2013","author":"N Granado","year":"2013","unstructured":"Granado N, Ares-Santos S, Moratalla R. Methamphetamine and Parkinson\u2019s disease. Parkinsons Dis. 2013;2013:308052. https:\/\/doi.org\/10.1155\/2013\/308052. (Epub 2013 Feb 7).","journal-title":"Parkinsons Dis"},{"issue":"6","key":"4147_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.870130605","volume":"13","author":"A Schrag","year":"1998","unstructured":"Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson\u2019s disease revisited\u2013clinical features, natural history, and mortality. Mov Disord. 1998;13(6):885\u201394. https:\/\/doi.org\/10.1002\/mds.870130605.","journal-title":"Mov Disord"},{"issue":"3","key":"4147_CR12","first-page":"83","volume":"30","author":"YT Chu","year":"2021","unstructured":"Chu YT, Tai CH, Lin CH, Wu RM. Updates on the genetics of Parkinson\u2019s disease: clinical implications and future treatment. Acta Neurol Taiwan. 2021;30(3):83\u201393.","journal-title":"Acta Neurol Taiwan"},{"issue":"2","key":"4147_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/mds.870020201","volume":"2","author":"N Quinn","year":"1987","unstructured":"Quinn N, Critchley P, Marsden CD. Young onset Parkinson\u2019s disease. Mov Disord. 1987;2(2):73\u201391. https:\/\/doi.org\/10.1002\/mds.870020201.","journal-title":"Mov Disord"},{"key":"4147_CR14","first-page":"1993","volume-title":"GeneReviews","author":"N Br\u00fcggemann","year":"2001","unstructured":"Br\u00fcggemann N, Klein C. Parkin type of early-onset Parkinson disease. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews. Seattle: University of Washington; 2001. p. 1993\u20132022."},{"issue":"2","key":"4147_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jnp.12227","volume":"15","author":"EM M\u00fcller-Oehring","year":"2021","unstructured":"M\u00fcller-Oehring EM, Fama R, Levine TF, Hardcastle C, Goodcase R, Martin T, Prabhakar V, Bront\u00eb-Stewart HM, Poston KL, Sullivan EV, Schulte T. Cognitive and motor deficits in older adults with HIV infection: comparison with normal ageing and Parkinson\u2019s disease. J Neuropsychol. 2021;15(2):253\u201373. https:\/\/doi.org\/10.1111\/jnp.12227. (Epub 2020 Oct 8).","journal-title":"J Neuropsychol"},{"issue":"2","key":"4147_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000341996","volume":"11","author":"D Weintraub","year":"2013","unstructured":"Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson\u2019s disease. Neurodegener Dis. 2013;11(2):63\u201371. https:\/\/doi.org\/10.1159\/000341996. (Epub 2012 Oct 3).","journal-title":"Neurodegener Dis"},{"issue":"3","key":"4147_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/mds.28320","volume":"36","author":"MDN Santin","year":"2021","unstructured":"Santin MDN, Voulleminot P, Vrillon A, Hainque E, B\u00e9reau M, Lagha-Boukbiza O, Wirth T, Montaut S, Bardinet E, Kyheng M, Rolland AS, Voirin J, Drapier S, Durif F, Eusebio A, Giordana C, Auzou N, Houeto JL, Hubsch C, Jarraya B, Laurencin C, Maltete D, Meyer M, Rascol O, Rouaud T, Tir M, Moreau C, Corvol JC, Proust F, Grabli D, Devos D, Tranchant C, Anheim M, Predistim Study Group. Impact of subthalamic deep brain stimulation on impulse control disorders in Parkinson\u2019s disease: a prospective study. Mov Disord. 2021;36(3):750\u20137. https:\/\/doi.org\/10.1002\/mds.28320. (Epub 2020 Oct 6).","journal-title":"Mov Disord"},{"issue":"12","key":"4147_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/jnnp-2017-315985","volume":"88","author":"N Warren","year":"2017","unstructured":"Warren N, O\u2019Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson\u2019s disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry. 2017;88(12):1060\u20134. https:\/\/doi.org\/10.1136\/jnnp-2017-315985. (Epub 2017 Oct 10).","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"4147_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.21803","volume":"23","author":"JS Reijnders","year":"2008","unstructured":"Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson\u2019s disease. Mov Disord. 2008;23(2):183\u20139. https:\/\/doi.org\/10.1002\/mds.21803. (quiz 313).","journal-title":"Mov Disord"},{"issue":"1","key":"4147_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","volume":"8","author":"D Aarsland","year":"2011","unstructured":"Aarsland D, P\u00e5hlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease\u2013epidemiology, mechanisms and management. Nat Rev Neurol. 2011;8(1):35\u201347. https:\/\/doi.org\/10.1038\/nrneurol.2011.189.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"4147_CR21","first-page":"37","volume":"89","author":"JA Borovac","year":"2016","unstructured":"Borovac JA. Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016;89(1):37\u201347.","journal-title":"Yale J Biol Med"},{"issue":"12","key":"4147_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11910-013-0409-5","volume":"13","author":"L Marsh","year":"2013","unstructured":"Marsh L. Depression and Parkinson\u2019s disease: current knowledge. Curr Neurol Neurosci Rep. 2013;13(12):409. https:\/\/doi.org\/10.1007\/s11910-013-0409-5.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"20","key":"4147_CR23","doi-asserted-by":"publisher","first-page":"10729","DOI":"10.26355\/eurrev_202010_23433","volume":"24","author":"N Zareifopoulos","year":"2020","unstructured":"Zareifopoulos N, Lagadinou M, Karela A, Pouliasi F, Economou I, Tsigkou A, Velissaris D. Efavirenz as a psychotropic drug. Eur Rev Med Pharmacol Sci. 2020;24(20):10729\u201335. https:\/\/doi.org\/10.26355\/eurrev_202010_23433.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04147-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T22:20:09Z","timestamp":1700518809000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04147-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4147"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04147-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2023,9,23]]},"assertion":[{"value":"1 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper was written in Singapore. Under the Domain Specific Review Board, specific ethics approval was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"405"}}